Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 3/20 | 0.49 |
| ▸ | CCND1 | P24385 | 3/20 | 0.49 |
| ▸ | CCND2 | P30279 | 3/20 | 0.49 |
| ▸ | CCND3 | P30281 | 3/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.44 |
| ▸ | AURKA | O14965 | 3/20 | 0.44 |
| ▸ | JAK3 | P52333 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | TYK2 | P29597 | 1/20 | 0.44 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 4/20 | 0.43 |
| ▸ | PLK1 | P53350 | 3/20 | 0.43 |
| ▸ | INSR | P06213 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355858 | 0.93 | EIF2AK4 (0.61) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355130 | 0.92 | EIF2AK4 (0.50) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355227 | 0.89 | CDK4 (0.47) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355878 | 0.87 | EIF2AK4 (0.49) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355821 | 0.85 | EIF2AK4 (0.62) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1356007 | 0.84 | EIF2AK4 (0.67) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1356682 | 0.84 | EIF2AK4 (0.61) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355771 | 0.83 | EIF2AK4 (0.64) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1353796 | 0.82 | EIF2AK4 (0.53) | EIF2AK4CDK4CCND1CCND2CCND3 | |
| SCHEMBL1355282 | 0.81 | KDR (0.46) | EIF2AK4CDK4CCND1CCND2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | claimed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | claimed |
| EP-2108020-A2 | 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | Biogen Idec MA, Inc. (US) | 2009-10-14 | — | — | EP | claimed |
| WO-2008094602-A2 | 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | claimed |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20100249067-A1 | Modulators of Mitotic Kinases | BIOGEN IDEC MA INC. (US) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249067-A1 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EIF2AK4 791/4885CDK4 101/4885CCND1 160/4885 |
| US-20110281821-A9 | Modulators of Mitotic Kinases | BUB1, BUB1B, CDK1 | EIF2AK4 791/4885CDK4 101/4885CCND1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.